Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 4/20 | 0.34 |
| ▸ | AKT2 | P31751 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876503 | 0.90 | PDE10A (0.45) | PDE10APDE4BAKT1AKT2MEN1 | |
| SCHEMBL4805276 | 0.88 | PDE10A (0.45) | PDE10APDE4BAKT1AKT2MEN1 | |
| SCHEMBL4810228 | 0.88 | MEN1 (0.47) | PDE10APDE4BAKT1AKT2MEN1 | |
| SCHEMBL4855612 | 0.87 | MEN1 (0.39) | PDE10APDE4BAKT1MEN1KMT2A | |
| SCHEMBL4879382 | 0.87 | PDE10A (0.49) | PDE10APDE4BAKT1AKT2MEN1 | |
| SCHEMBL4869091 | 0.86 | PDE10A (0.45) | PDE10APDE4BAKT1AKT2MEN1 | |
| SCHEMBL4809409 | 0.86 | PTGS2 (0.36) | PDE10APDE4BAKT1AKT2MEN1 | |
| SCHEMBL4869914 | 0.86 | PDE4B (0.35) | PDE10APDE4BAKT1AKT2MEN1 | |
| SCHEMBL4869201 | 0.85 | PDE4B (0.35) | PDE10APDE4BAKT1AKT2MEN1 | |
| SCHEMBL4856160 | 0.85 | PDE10A (0.46) | PDE10APDE4BAKT1AKT2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | claimed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | PDE10A 8/4885PDE4B 12/4885AKT1 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.